Elanco Animal Health (NYSE:ELAN) Reaches New 1-Year High - Should You Buy?

Key Points

• Elanco Animal Health's stock price reached a new 52-week high of $18.95 during trading, closing at $18.72 with significant trading volume.
• Analysts have mixed ratings on Elanco, with a current average rating of "Moderate Buy" and a target price of $17.33, while some have upgraded their ratings recently.
• The company reported earnings of $0.26 per share for the last quarter, exceeding projections and showing a 4.8% year-over-year revenue increase.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $18.95 and last traded at $18.72, with a volume of 103016 shares changing hands. The stock had previously closed at $17.90.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of recent analyst reports. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. Zacks Research lowered shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. Piper Sandler boosted their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, August 11th. Finally, Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $17.33.

Elanco Animal Health Trading Down 0.4%

The firm has a market capitalization of $9.13 billion, a P/E ratio of 21.37, a price-to-earnings-growth ratio of 3.42 and a beta of 1.66. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The business's 50-day moving average is $15.55 and its 200 day moving average is $12.69.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.19 billion. During the same quarter last year, the business earned $0.30 earnings per share. Elanco Animal Health's revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. MTM Investment Management LLC boosted its holdings in shares of Elanco Animal Health by 5.5% in the 2nd quarter. MTM Investment Management LLC now owns 15,268 shares of the company's stock valued at $218,000 after purchasing an additional 800 shares in the last quarter. HighTower Advisors LLC boosted its holdings in shares of Elanco Animal Health by 7.0% in the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company's stock valued at $131,000 after purchasing an additional 810 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Elanco Animal Health by 8.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company's stock valued at $169,000 after purchasing an additional 944 shares in the last quarter. M&T Bank Corp boosted its holdings in shares of Elanco Animal Health by 4.0% in the 2nd quarter. M&T Bank Corp now owns 25,029 shares of the company's stock valued at $358,000 after purchasing an additional 971 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Elanco Animal Health by 8.7% in the 2nd quarter. ProShare Advisors LLC now owns 12,439 shares of the company's stock valued at $178,000 after purchasing an additional 999 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.